Anzeige
❌
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A0LCUJ | ISIN: FR0010331421 | Ticker-Symbol: IDD
Tradegate
24.04.25
07:38 Uhr
1,768 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INNATE PHARMA SA Chart 1 Jahr
5-Tage-Chart
INNATE PHARMA SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,7621,77609:12
1,7521,78409:08

Aktuelle News zur INNATE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
00:59Sanofi Invests €15 Mln In Innate Pharma To Support Pipeline And Extend Cash Runway2RTTNews
DoH.C. Wainwright maintains $11 target on Innate Pharma stock1Investing.com
INNATE PHARMA Aktie jetzt für 0€ handeln
DoInnate Pharma SA: Innate Pharma Announces €15M Investment by Sanofi199Business WireInvestment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeting ANKET program in autoimmune indications, and more Regulatory...
► Artikel lesen
MiInnate Pharma SA - 6-K, Report of foreign issuer3SEC Filings
MiInnate Pharma SA: Innate Pharma Regains Its Rights on CD123 Targeting ANKET and Announces Sanofi's Intention to Make a Strategic Investment in the Company254Business WireInnate to regain its rights on CD123 targeting ANKET SAR443579 (SAR'579) /IPH6101 currently in development for AML Potential investment of up to €15M by Sanofi in Innate Pharma through...
► Artikel lesen
16.04.Innate Pharma SA - 6-K, Report of foreign issuer1SEC Filings
16.04.Innate Pharma SA: Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025404Business WireRegulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") will hold its annual general meeting of shareholders ("AGM") at 10:30 a.m. CEST on May 22, 2025...
► Artikel lesen
16.04.Innate Pharma SA: Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition421Business WireInnate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors ...
► Artikel lesen
03.04.Innate Pharma SA - 6-K, Report of foreign issuer-SEC Filings
03.04.Innate Pharma SA: Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum253Business WireRegulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team will present and host 1x1 meetings at the Stifel...
► Artikel lesen
29.03.Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Call Transcript1Insider Monkey
28.03.H.C. Wainwright maintains Buy rating on Innate Pharma stock1Investing.com
27.03.Innate Pharma SA - 6-K, Report of foreign issuer-SEC Filings
27.03.Innate Pharma reports FY results3Seeking Alpha
27.03.Innate Pharma SA: Innate Pharma Reports Full Year 2024 Financial Results and Business Update309Business WireFDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from...
► Artikel lesen
26.03.Innate Pharma SA: Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting281Business WireIPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. IPH4502 demonstrated preclinical anti-tumor...
► Artikel lesen
25.03.Innate Pharma SA: Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference337Business WireRegulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team are scheduled to participate in the upcoming...
► Artikel lesen
20.03.Innate Pharma SA - 6-K, Report of foreign issuer1SEC Filings
20.03.Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results297Business WireRegulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Thursday, March 27, 2025 at 2...
► Artikel lesen
27.02.Innate Pharma SA - 6-K, Report of foreign issuer-SEC Filings
Seite:  1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1